NCT04457869Unknown2 期
A Phase 2, Open-label, Single-arm, Multicenter Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 43
- 主要终点
- Objective response rate (ORR) by Independent Review Committee (IRC) Independent Review Committee (IRC).
研究概览
简要总结
It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of F520 for the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female of 18 Years and older;
- •Pathologically confirmed PCNSL or SCNSL of primary testicular diffuse large B-cell lymphoma (PT-DLBCL) who failed or did not respond to at least 1 line of systemic therapy; Recurrence and refractory should meet the following definitions:
- •PCNSL patients: relapse is defined as the appearance of new lesions at the primary site or other sites after the standard treatment with MTX reaches complete remission (CR). Refractory patients were defined as those who did not reach PR in 2 cycles or CR in 4 cycles after standard treatment with MTX. If the best effect or end cause was PD, the number of courses was not required;
- •patients with SCNSL: Patients with relapsed/refractory primary testicular diffuse large B-cell lymphoma who must include central nervous system invasion. Relapse was defined as the patients who had been prevented or treated with MTX; refractory was defined as the patients who had received the latest chemotherapy regimen for 2 cycles without PR or 4 cycles without CR. if the best effect or end cause was PD, the number of courses was not required;
- •Measurable disease requirements on scans: subjects should have at least one measurable extranodal brain lesion more than 10×10mm;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0~2;
- •Agree to provide archived tumor tissue specimens or fresh tissue specimens;
- •Life expectancy ≥ 3 months;
- •Adequate laboratory parameters during the screening period as evidenced by the following（No blood components and cell growth factors are allowed within 14 days prior to screening）:
- •routine blood tests: Absolute neutrophil count ≥1.5×109/L ;Platelets ≥100×109/L;Hemoglobin ≥ 9.0 g/dL; Liver function：Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), ALT and AST ≤2.5ULN; for subjects with liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5×ULN, Total bilirubin (TBIL) ≤3×upper limit of normal (ULN); Renal function CCr≤1.5×ULN，Creatinine clearance≥50 mL/min; Thyroid function indicators: thyroid-stimulating hormone (TSH) and free thyroxine (FT3/FT4) are within the normal range or no clinical significant;
- •International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal;
- •Understand study procedures and contents, and voluntarily sign the written informed consent form.
排除标准
- •a）Patients with suspected or existing eye tumors; b）patients who cannot undergo MRI assessments c) PCNSL patients with systemic disease;
- •Patients with certain diseases such as active autoimmune disease, type I diabetes, hypothyroidism that needs hormone replacement, active infection, psychiatric disorder (Except for mild cognitive impairment caused by tumor);
- •Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast;
- •Patients with stroke within 6 months before the first dose (except for those with "multiple lacunar infarction" indicated by imaging examination, but no need for treatment) or with a history of intracranial hemorrhage (except for intracranial hemorrhage after surgery);
- •Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways;
- •Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses > 10 mg/day prednisone or equivalent are prohibited within 14 days before the first dose;
- •Active infection（needing therapy） or an unexplained fever > 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);
- •Those who received systemic therapy of radiotherapy, chemotherapy, hormone therapy, surgery, targeted therapy, or antibody drugs within 4 weeks before the first dose; used monoclonal antibody coupled radionuclide or cytotoxic therapy within 10 weeks before the first dose; the toxicity of previous anti-tumor therapy has not recovered to ≤1 (except hair loss);
- •Patients who have a history of organ transplantation or allogeneic bone marrow transplantation or who have received auto stem cell transplantation or other severe immune defects within 3 months before the first dose;
- •Patients who are preparing for autologous stem cell transplantation.
- •Patients with active pulmonary tuberculosis;
- •Previous or simultaneous interstitial lung disease (except for interstitial lung disease caused by radiotherapy and chemotherapy and without symptoms at present);
- •Patients with active hepatitis;
- •Patients with HIV positive;
- •Patients received any other clinical trial drug / device treatment within 4 weeks before the first administration;
- •Patients with uncontrollable or serious cardiovascular diseases, cardiovascular diseases such as congestive heart failure, unstable angina pectoris, myocardial infarction and other cardiovascular diseases of NYHA grade II or above occurred within 6 months before the first dose; uncontrolled hypertension (systolic pressure ≥ 180mmhg and / or diastolic pressure ≥ 100mmhg);
- •Patients with drug abuse history or alcohol addiction history within 6 months before the study drug administration;
- •Patients with known previous allergies to macromolecular protein preparations or known to be allergic to anti-PD-1 / PD-L1 antibodies
- •Patients who received live attenuated vaccine within 4 weeks before the first dose (except inactivated influenza vaccine such as seasonal influenza vaccine for injection);
- •Female and male who have reproductive potential must be willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy while on treatment and for at least 6 months after receiving the last dose of study treatment.
- •The investigators judged that it was not suitable for the patients to participating in the study.
研究组 & 干预措施
Single arm
Experimental
干预措施: F520 (Drug)
结局指标
主要结局
Objective response rate (ORR) by Independent Review Committee (IRC) Independent Review Committee (IRC).
时间窗: Approximately 24 months
Response assessment will be performed according to modified IPCG response. criteria on contrastenhanced cranial MRI-scans.
次要结局
- Progression-free survival (PFS)(Approximately 24 months)
- Overall survival (OS)(Approximately 24 months)
- Safety of F520(Approximately 24 months)
- Objective response rate (ORR) based on the investigator assessment.(Approximately 24 months)
- Duration of response (DOR)(Approximately 24 months)
研究者
相似试验
Unknown
2 期
The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).Peripheral T Cell LymphomaNCT04457830Shandong New Time Pharmaceutical Co., LTD105
已完成
2 期
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDBreast CancerNCT05520723MedSIR50
进行中（未招募）
不适用
A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to systemic anticancer therapyEUCTR2007-005670-31-ATCelgene Corporation167
招募中
1 期
A study to evaluate safety and efficacy of SOT101 in combination with pembrolizumab in patients with selected advanced/refractory solid tumorsEUCTR2021-005774-25-BESOTIO Biotech AG320
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of SOT101 in combination with cetuximab in patients with a specific subtype of colon and/or rectum cancerRAS wild-type colorectal cancerEUCTR2022-001527-32-BESOTIO Biotech AG52